Home › Non-Small Cell Lung Cancer › Kansas
Non-Small Cell Lung Cancer clinical trials in Kansas
34 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Kansas.
Cities in Kansas
- Overland Park16 studies
- Kansas City11 studies
- Olathe7 studies
- Salina7 studies
- Topeka7 studies
- Hays6 studies
- Lawrence6 studies
- Wichita5 studies
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- The University of Kansas Cancer Center - Olathe, Olathe
- Cancer Center of Kansas - Pratt, Pratt
- Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- Ascension Via Christi Hospitals Wichita, Wichita
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07293247Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- HaysMed, Hays
- Lawrence Memorial Hospital, Lawrence
- The University of Kansas Cancer Center - Olathe, Olathe
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06498635Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Kansas City Cancer Center /ID# 273679, Overland Park
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- The University of Kansas Cancer Center, Westwood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- University of Kansas Cancer Center, Westwood
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05498428Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Westwood
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06218914This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Saint Luke's South Hospital, Overland Park
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- University of Kansas Cancer Center, Fairway
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06667076A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Research Site, Leawood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06868277Pan-tumor MRD Study
- Cotton O'Neil Cancer Center [Stormont Vail], Topeka
- Cancer Center of Kansas, Wichita
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- Central Care Cancer Center - Garden City, Garden City
- Central Care Cancer Center - Great Bend, Great Bend
- Mercy Hospital Pittsburg, Pittsburg
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT03191149A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Cancer Center of Kansas, Wichita
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06561386A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- University of Kansas, Westwood
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07020117Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-942-B, Chanute
- Local Institution - 007-942-D, El Dorado
- Local Institution - 007-942-E, Independence
- and 12 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT04613596Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- University of Kansas Medical Center /ID# 263196, Westwood
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06236438A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- The University of Kansas Cancer Center - Westwood, Westwood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- University of Kansas Medical Center, Kansas City
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06343402Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06500481A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Kansas Cancer Center, Kansas City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- University of Kansas Medical Center (KUMC), Westwood
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- The University of Kansas Cancer Center, Investigational Drug Services, Fairway
- The University of Kansas Clinical Research Center, Fairway
- The University of Kansas Hospital, Kansas City
- and 6 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- University of Kansas Cancer Center, Westwood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jun 25, 2026 · NCT06216301A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- The University of Kansas Cancer Center, Westwood
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Jun 11, 2026 · NCT05361174Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- and 7 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 3, 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- and 7 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 6, 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- and 7 more
RecruitingPhase 2
18 Minutes · All sexes · Updated May 5, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- University of Kansas Clinical Research Center, Fairway
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- and 8 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated May 5, 2026 · NCT06616584A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- The University of Kansas Cancer Center, Fairway
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 18, 2026 · NCT06244771Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- HaysMed, Hays
- Lawrence Memorial Hospital, Lawrence
- The University of Kansas Cancer Center - Olathe, Olathe
- and 6 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Mar 17, 2026 · NCT06418204Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
- The University of Kansas Cancer Center (KUCC), Fairway
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 28, 2026 · NCT04467723A Study of IBI363 in Subjects with Advanced Solid Malignancies
- University of Kansas Medical Center (KUMC), Fairway
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 19, 2024 · NCT06281678Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 8, 2024 · NCT04680377Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
- The University of Kansas Cancer Center (KUCC), Fairway
- The University of Kansas Cancer Center, Westwood Campus, Kansas City
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Feb 23, 2024 · NCT05332925From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.